India's pharmaceutical sector is embracing artificial intelligence in the earliest, hardest stages of making new medicines.
According to The Hindu BusinessLine, Aurigene Pharmaceutical Services — an arm of Dr. Reddy's Laboratories — has launched Aurigene.AI, an AI and machine-learning-assisted platform built to accelerate drug discovery projects. The report says the platform is designed to help move projects along starting from "hit identification," the early phase in which researchers screen for chemical compounds that show promise against a disease target.
Drug discovery is notoriously slow and expensive, often taking years of laboratory work before a candidate is ready for testing. Tools that use AI and machine learning aim to narrow the field of possibilities faster, letting scientists focus on the most promising molecules earlier in the process.
Aurigene is not alone in this push. Mediabrief.com reports that Mankind Pharma has separately launched an AI drug discovery effort in partnership with Denovo Sciences. Together, the two announcements point to a broader trend of Indian drug makers folding AI into their research pipelines rather than treating it as a side experiment.
The sources provided do not detail the specific technologies behind either platform, the diseases being targeted, or any results achieved so far.
Why it matters: If AI can reliably shorten the front end of drug discovery, it could lower the cost and time of bringing new treatments to patients — and these moves suggest India's large generic-drug industry is positioning itself to compete in that emerging race.